Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1 31Phase 1/2 19Phase 3 4

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 1Lymphoma 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × romidepsin × Clear all
NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Celgene

Phase 3 Active not recruiting
93 enrolled 19 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell

NCT01796002 2023-01-10

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

The Lymphoma Academic Research Organisation

Phase 3 Completed
421 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03355768 2018-12-19

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Columbia University

Phase 3 Withdrawn
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Takeda

Phase 3 Completed
271 enrolled 25 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡